Merck & Co. asserted that late-stage data for its two-drug combination of doravirine and islatravir shows the treatment’s potential as an alternative to therapies containing integrase inhibitors, which could prove important as the HIV patient population ages and the need for drugs that carry lower risk of long-term toxicity increases.
Key Takeaways
- Merck presented data from two Phase III studies of doravirine/islatravir in patients with HIV, showing non-inferiority to both Gilead’s Biktarvy and to other HIV therapies.
- The company is touting the drug as providing an alternative to existing therapies that does not contain an integrase inhibitor
The Rahway, NJ-based drug maker shared results on 12 March from the Phase III MK-8591A-052 trial testing doravirine/islatravir (DOR/ISL) against the current market leader, Gilead Sciences’ Biktarvy (bictegravir/emtricitabine/tenofovir) and from the open-label Phase III MK-8591A-051 trial testing DOR/ISL against baseline antiretroviral therapies (bART)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
